MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Synta Pharmaceuticals Corp. (SNTA) Adds Steven Bernitz As New Senior Vice President, Corporate Development 0 comments
    Dec 23, 2013 2:29 PM | about stocks: SNTA

    Synta Pharmaceuticals announced earlier today the recruitment of Steven Bernitz to the position of Senior Vice President, Corporate Development. Bernitz brings with him over 20 years of experience in corporate strategy, business leadership and transactional experience in life sciences.

    Prior to Synta, Bernitz was a General Partner and Head of the BioPharma Practice at Extera Partners, a business development advisory firm. While at Extera, Bernitz directed a number of business development and strategy initiatives for development stage companies and their investors in areas such as autoimmune, oncology, and orphan diseases.

    Before joining Extera in 2010, Bernitz held the role of Chief Business Officer at Concert Pharmaceuticals where he oversaw Concert's $1 billion deal with GlaxoSmithKline. Prior to Concert he sat as Senior Vice President, Business and Product Development at Coley Pharmaceutical Group, where he led a plethora of transactions including Coley's $600 million oncology deal with Pfizer. In addition, Bernitz's experience includes acting as CEO of Histogenics and Organogenesis, both cell therapy companies, and before that he was with Merck Vaccines and McKinsey & Co.

    "Steve has tremendous deal experience, as is clear from his track record, which will be valuable in realizing the potential of both our ganetespib and HDC programs," stated Safi Bahcall, President and CEO, Synta. "His wealth of diverse business experiences and insights make him an excellent addition to our executive team, as we manage a growing pipeline and an increasing number of important strategic and operational choices."

    "Synta has the potential to make a tremendous difference in the lives of cancer patients," commented Bernitz. "Both ganetespib and the HDC platform represent innovative new treatment approaches that can transform standard of care. I am excited to join the team and help achieve these ambitious goals."

    Bernitz holds an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University, where he was an Austin Scholar. His B.S. summa cum laude is from Tufts University, where he was elected to Phi Beta Kappa.

    For more information, please visit syntapharma.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: SNTA
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.